First-round winners in the #FierceMadness ad tournament are decided, with the victors advancing to compete in Round 2's field of 32.
Pfizer and Merck KGaA haven’t had much luck with Bavencio in ovarian cancer, so the pair are calling it quits on a late-stage trial.
CDMO Thermo Fisher Scientific is investing $150 million to expand biologics and sterile manufacturing at one site in the U.S. and two in Italy.
Merck continues its HPV awareness campaign with a twist. In new TV, a parent is the narrator for the first time in the three-year-old campaign.
AbbVie's efforts to protect Humira violate antitrust laws and consumer protection laws, a grocery union argued in a new class action lawsuit.
Sage Therapeutics has a green light for postpartum depression drug Zulresso. But it also has some big challenges ahead.
Starboard Value's 197-page presentation against the BMS-Celgene deal lacks a "smoking gun," an analyst wrote. He believes the deal will go…
AbbVie and Roche are looking to move Venclexta deeper into the blood cancer arena, but their multiple myeloma ambitions just took a hit.
Bayer's sale of its animal health unit is attracting interest from a wide variety of players, including private equity firms and even rivals, a new report…
Just a week after Roche’s Tecentriq became the first FDA-approved I-O agent in breast cancer, the drug has clinched another first-in-class nod.